Literature DB >> 29792889

ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.

Zhi Liu1, Jing Qiao1, Tamas Nagy2, May P Xiong3.   

Abstract

Iron-mediated generation of highly toxic Reactive Oxygen Species (ROS) plays a major role in the process leading to iron overload-related diseases. The long-term subcutaneous administration of Deferoxamine (DFO) is currently clinically-approved to improve patient symptoms and survival. However, non-specific toxicity and short circulation times of the drug in humans often leads to poor patient compliance. Herein, thioketal-based ROS-responsive polymeric nanogels containing DFO moieties (rNG-DFO) were designed to chelate iron and to degrade under oxidative stimuli into fragments <10 nm to enhance excretion of iron-bound chelates. Serum ferritin levels and iron concentrations in major organs of IO mice decreased following treatment with rNG-DFO, and fecal elimination of iron-bound chelates increased compared to free DFO. Furthermore, rNG-DFO decreased iron mediated oxidative stress levels in vitro and reduced iron-mediated inflammation in the liver of IO mice. The study confirms that ROS-responsive nanogels may serve as a promising alternative to DFO for safer and more efficient iron chelation therapy.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chelation therapy; Deferoxamine (DFO); Iron overload (IO); Nanogel; Reactive oxygen species (ROS)

Mesh:

Substances:

Year:  2018        PMID: 29792889      PMCID: PMC6035766          DOI: 10.1016/j.jconrel.2018.05.025

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  41 in total

1.  CHELATION OF FERROUS SULPHATE SOLUTIONS BY DESFERRIOXAMINE B.

Authors:  J F GOODWIN; C F WHITTEN
Journal:  Nature       Date:  1965-01-16       Impact factor: 49.962

Review 2.  Iron overload cardiomyopathy in clinical practice.

Authors:  Dimitrios T Kremastinos; Dimitrios Farmakis
Journal:  Circulation       Date:  2011-11-15       Impact factor: 29.690

Review 3.  Reactive Oxygen Species (ROS) Responsive Polymers for Biomedical Applications.

Authors:  Qinghua Xu; Chaoliang He; Chunsheng Xiao; Xuesi Chen
Journal:  Macromol Biosci       Date:  2016-02-18       Impact factor: 4.979

Review 4.  Iron overload cardiomyopathy: better understanding of an increasing disorder.

Authors:  Pradeep Gujja; Douglas R Rosing; Dorothy J Tripodi; Yukitaka Shizukuda
Journal:  J Am Coll Cardiol       Date:  2010-09-21       Impact factor: 24.094

5.  The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis.

Authors:  P C Adams; Y Deugnier; R Moirand; P Brissot
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

Review 6.  Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations.

Authors:  Balaraman Kalyanaraman; Victor Darley-Usmar; Kelvin J A Davies; Phyllis A Dennery; Henry Jay Forman; Matthew B Grisham; Giovanni E Mann; Kevin Moore; L Jackson Roberts; Harry Ischiropoulos
Journal:  Free Radic Biol Med       Date:  2011-10-02       Impact factor: 7.376

7.  Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.

Authors:  C Niederau; R Fischer; A Sonnenberg; W Stremmel; H J Trampisch; G Strohmeyer
Journal:  N Engl J Med       Date:  1985-11-14       Impact factor: 91.245

8.  Direct evidence for in vivo hydroxyl-radical generation in experimental iron overload: an ESR spin-trapping investigation.

Authors:  M J Burkitt; R P Mason
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

9.  How I treat transfusional iron overload.

Authors:  A Victor Hoffbrand; Ali Taher; Maria Domenica Cappellini
Journal:  Blood       Date:  2012-08-23       Impact factor: 22.113

10.  Sub-10-nm Pd nanosheets with renal clearance for efficient near-infrared photothermal cancer therapy.

Authors:  Shaoheng Tang; Mei Chen; Nanfeng Zheng
Journal:  Small       Date:  2014-04-14       Impact factor: 13.281

View more
  9 in total

1.  Combating iron overload: a case for deferoxamine-based nanochelators.

Authors:  Gregory Jones; Sumanta Kumar Goswami; Homan Kang; Hak Soo Choi; Jonghan Kim
Journal:  Nanomedicine (Lond)       Date:  2020-05-20       Impact factor: 5.307

2.  Synthesis and evaluation of an amphiphilic deferoxamine:gallium-conjugated cationic random copolymer against a murine wound healing infection model of Pseudomonas aeruginosa.

Authors:  Jing Qiao; Zhi Liu; Shuolin Cui; Tamas Nagy; May P Xiong
Journal:  Acta Biomater       Date:  2021-03-08       Impact factor: 8.947

3.  Renal clearable nanochelators for iron overload therapy.

Authors:  Homan Kang; Murui Han; Jie Xue; Yoonji Baek; JuOae Chang; Shuang Hu; HaYoung Nam; Min Joo Jo; Georges El Fakhri; Michael P Hutchens; Hak Soo Choi; Jonghan Kim
Journal:  Nat Commun       Date:  2019-11-13       Impact factor: 14.919

Review 4.  Micro- to Nanoscale Bio-Hybrid Hydrogels Engineered by Ionizing Radiation.

Authors:  Clelia Dispenza; Daniela Giacomazza; Mats Jonsson
Journal:  Biomolecules       Date:  2020-12-31

5.  Injectable Thermosensitive Hydrogels for a Sustained Release of Iron Nanochelators.

Authors:  Seung Hun Park; Richard S Kim; Wesley R Stiles; Minjoo Jo; Lingxue Zeng; Sunghoon Rho; Yoonji Baek; Jonghan Kim; Moon Suk Kim; Homan Kang; Hak Soo Choi
Journal:  Adv Sci (Weinh)       Date:  2022-03-27       Impact factor: 17.521

Review 6.  Nanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics.

Authors:  Yunhan Zhang; Zhulin Zou; Shuang Liu; Shengjie Miao; Haiyan Liu
Journal:  Front Bioeng Biotechnol       Date:  2022-07-19

7.  New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis.

Authors:  Wenya Feng; Yuanjing Xiao; Chuanfang Zhao; Zhanming Zhang; Wei Liu; Juan Ma; Tomas Ganz; Junliang Zhang; Sijin Liu
Journal:  Adv Sci (Weinh)       Date:  2022-08-28       Impact factor: 17.521

Review 8.  Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.

Authors:  Amy Corbin Farr; May P Xiong
Journal:  Mol Pharm       Date:  2020-10-09       Impact factor: 4.939

9.  Alzheimer's Disease and Its Potential Alternative Therapeutics.

Authors:  Brent Kisby; Juliet T Jarrell; M Enes Agar; David S Cohen; Eric R Rosin; Catherine M Cahill; Jack T Rogers; Xudong Huang
Journal:  J Alzheimers Dis Parkinsonism       Date:  2019-09-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.